TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has issued an announcement.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced the scheduling of its 2025 second extraordinary general meeting (EGM) to be held on December 2, 2025, in Shanghai. The primary agenda is to elect Mr. Liu Yi as an executive director. This meeting reflects the company’s ongoing efforts to strengthen its leadership structure, which could have implications for its strategic direction and stakeholder engagement.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, operating in the pharmaceutical industry. The company focuses on the development, manufacturing, and distribution of pharmaceutical products and healthcare services.
Average Trading Volume: 9,657,638
Technical Sentiment Signal: Buy
Current Market Cap: HK$77.49B
For an in-depth examination of 2196 stock, go to TipRanks’ Overview page.